Predictive Accuracy of PLR and PNR in Detecting ETIC

Launched by JUBILEE MISSION MEDICAL COLLEGE AND RESEARCH INSTITUTE · Jun 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well two blood test measurements—the platelet-neutrophil ratio (PNR) and the platelet-lymphocyte ratio (PLR)—can predict early trauma-induced coagulopathy, a condition where the blood’s ability to clot is affected after an injury. The study focuses on patients who come to the emergency department within 6 hours of experiencing trauma. Researchers want to see if these simple blood tests can help doctors quickly identify patients at risk for this blood clotting problem during their hospital stay.

To be part of this study, patients must have had a trauma injury and arrived at the emergency department within 6 hours of the event, with their doctor ordering a blood clotting test. People who received treatment like fluids or blood products elsewhere, or who suffered certain types of injuries like drowning, hanging, or burns, won’t be eligible. Also, patients on medications or with medical conditions affecting blood clotting won’t be included. If eligible, participants will have their blood tested as part of routine care, and the study will observe these results to learn more, without changing the treatment they receive. This research may help improve how doctors detect and manage blood clotting problems early after trauma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients with trauma AND
• • Presenting to ED within 6 hours of the event AND
• • The ED Physician sends coagulation profile
• Exclusion Criteria:
• • Treated with intravenous fluids, drugs, whole blood and blood products elsewhere
• • Patients admitted with a non-mechanical mechanism of injury, specifically drowning, hanging,or burns, as these mechanisms may result in a different biologic response than mechanical trauma
• • Patients on known medications affecting coagulation profile or hemogram
• • Patients with known chronic liver disease, chronic renal failure, malignancy, hematological disorders
• • Patients not consenting for the study